Evidence map›Paper›PMID 22584867›Full record

ArticleMolecular psychiatry2012

Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.

M Ayalew, H Le-Niculescu, D F Levey, N Jain, B Changala, S D Patel, E Winiger, A Breier, A Shekhar, R Amdur and 10 more

Abstract read
In one paragraph

Article in Molecular psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 206 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
206citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

206 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. The Gene Encoding Protocadherin 9 (PCDH9), a Novel Risk Factor for Major Depressive Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Pooled it
  3. Pooled it
  4. Pooled it
  5. The relationship between schizophrenia and rheumatoid arthritis revisited: genetic and epidemiological analyses.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2015
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Genetic and immune landscape of keratoconus: insights from Mendelian randomization analysis.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
  18. Article
  19. Review
  20. Review

146 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

M AyalewDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
H Le-Niculescu
D F Levey
N Jain
B Changala
S D Patel
E Winiger
A Breier
A Shekhar
R Amdur
D Koller
J I Nurnberger
A Corvin
M Geyer
M T Tsuang
D Salomon
N J Schork
A H Fanous
M C O'Donovan
A B Niculescu

Funding

Developing Blood Tests for Mood DisordersDP2OD007363 · OD · INDIANA UNIVERSITY INDIANAPOLIS · PI NICULESCU, ALEXANDER B · 2010 to 2010
$2.3M
Mood State Blood Biomarkers: A Discovery-Based ApproachI01CX000139 · VA · RLR VA MEDICAL CENTER · PI NICULESCU, ALEXANDER B · 2009 to 2017
–
CSRD VA I01 CX000139Medical Research Council G0800509NIH HHS 1DP2OD007363NIH HHS DP2 OD007363
6 · The paper itself

Abstract

We have used a translational convergent functional genomics (CFG) approach to identify and prioritize genes involved in schizophrenia, by gene-level integration of genome-wide association study data with other genetic and gene expression studies in humans and animal models. Using this polyevidence scoring and pathway analyses, we identify top genes (DISC1, TCF4, MBP, MOBP, NCAM1, NRCAM, NDUFV2, RAB18, as well as ADCYAP1, BDNF, CNR1, COMT, DRD2, DTNBP1, GAD1, GRIA1, GRIN2B, HTR2A, NRG1, RELN, SNAP-25, TNIK), brain development, myelination, cell adhesion, glutamate receptor signaling, G-protein-coupled receptor signaling and cAMP-mediated signaling as key to pathophysiology and as targets for therapeutic intervention. Overall, the data are consistent with a model of disrupted connectivity in schizophrenia, resulting from the effects of neurodevelopmental environmental stress on a background of genetic vulnerability. In addition, we show how the top candidate genes identified by CFG can be used to generate a genetic risk prediction score (GRPS) to aid schizophrenia diagnostics, with predictive ability in independent cohorts. The GRPS also differentiates classic age of onset schizophrenia from early onset and late-onset disease. We also show, in three independent cohorts, two European American and one African American, increasing overlap, reproducibility and consistency of findings from single-nucleotide polymorphisms to genes, then genes prioritized by CFG, and ultimately at the level of biological pathways and mechanisms. Finally, we compared our top candidate genes for schizophrenia from this analysis with top candidate genes for bipolar disorder and anxiety disorders from previous CFG analyses conducted by us, as well as findings from the fields of autism and Alzheimer. Overall, our work maps the genomic and biological landscape for schizophrenia, providing leads towards a better understanding of illness, diagnostics and therapeutics. It also reveals the significant genetic overlap with other major psychiatric disorder domains, suggesting the need for improved nosology.

Indexed as

AnimalsCase-Control StudiesDatabases, GeneticDisease Models, AnimalGenetic Association StudiesGenetic Predisposition to DiseaseGenomicsHumansMental DisordersPolymorphism, Single NucleotideReelin ProteinSchizophreniaReelin Protein

Identifiers

PMID22584867
PMCPMC3427857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.